Filing Flows › Twist Bioscience (TWST) › How it makes money
How Twist Bioscience (TWST) makes money
Twist Bioscience (TWST) made $118M of revenue in the third quarter fiscal 2026 (Q3 FY26), +23% from a year earlier. NGS applications brought in $61.8M (52%); DNA synthesis and protein solutions brought in $56.6M (48%).
Drawing the Sankey…
Revenue by segment, Q3 FY26
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| NGS applications | $61.8M | 52.2% | +8% | +12% |
| DNA synthesis and protein solutions | $56.6M | 47.8% | +6% | +39% |
Where each dollar of revenue goes
| Line | Q3 FY26 | % of revenue |
|---|---|---|
| Revenue | $118M | 100.0% |
| Income tax | $311K | 0.3% |
| Operating cash flow | $1.1M | 0.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 FY26 | $118M | +23% |
| Q2 FY26 | $111M | +19% |
| Q1 FY26 | $104M | +17% |
| Q4 FY25 | $99.0M | +17% |
| Q3 FY25 | $96.1M | +18% |
| Q2 FY25 | $92.8M | +23% |
| Q4 FY24 | $84.7M | +26% |
From Twist Bioscience's 10-Q filed Aug 3, 2026 (on EDGAR).
Questions
How does Twist Bioscience make money?
Twist Bioscience (TWST) made $118M of revenue in the third quarter fiscal 2026 (Q3 FY26), +23% from a year earlier. NGS applications brought in $61.8M (52%); DNA synthesis and protein solutions brought in $56.6M (48%).
What is Twist Bioscience's biggest business?
NGS applications: $61.8M in the third quarter fiscal 2026, 52% of revenue, +12% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.